Document is current
Any future updates will be listed below
-
Authors
Vacarezza, Cristóbal
Araneda, Julieta
Gonzalez, Pamela
Arteaga, Oscar
Marcelain, Katherine
Castellon, Enrique A.
Periera, Ana
Khoury, Maroun
Müller, Bettina
Lecaros, Juan Alberto
Salas, Sofia P.
Riquelme, Arnoldo
Corvalan, Alejandro H.
de la Jara, Jorge Jiménez
Ferreccio, Catterina
Goic, Carolina
Nervi, Bruno
Roa, Juan Carlos
Owen, Gareth I. https://orcid.org/0000-0003-3807-6054
-
Funding
Funding for this research was provided by:
ANID FONDAP (152220002)
ANID-FONDAP (15130011, 1523A0008)
Instituto Milenio en Inmunología e Inmunoterapia (PROGRAMA ICM-ANID, ICN2021_045)
ANID-FONDECYT (1220586)
HORIZON EUROPE Framework Programme (825741)
ANID-Anillo (ACT210079)
ANID-Basal (FB210024)
- License Information
-
More Information
Article History
Received: 2 July 2024
Accepted: 18 November 2024
First Online: 18 December 2024
Declarations
:
: MK is the Chief scientific officer from Cells for Cells, a university spin-off developing cell therapies for Osteoarthritis, and Regenero, a consortium for Chilean regenerative medicine (public and private funding), for autoimmune diseases. The other authors declare that no conflicts of interest are present.
: Not applicable. This manuscript does not contain interventional research on human or animal subjects.
: This article has been read and approved for publication by all authors.
